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Abstract: Retinal ganglion cell (RGC) death is a hallmark of neurodegenerative diseases and 
disease processes of the eye, including glaucoma. The protection of RGCs has been an   important 
strategy for combating glaucoma, but little clinical success has been reported to date. One 
pathophysiological consequence of glaucoma is excessive extracellular glutamate subsequently 
leading to excitotoxicity in the retina. Endocannabinoids, such as the N-acylethanolamine 
(NAE), arachidonylethanolamine (NAE 20:4), exhibit neuroprotective properties in some 
models of neurodegenerative disease. The majority of NAEs, however, are not cannabinoids, 
and their physiological function is not clear. Here, we determined whether the noncannabinoid 
NAE, linoleoylethanolamine (NAE18:2), protects neurons in the RGC layer against glutamate 
excitotoxicity in ex-vivo retina cultures. Using a terminal deoxynucleotidyl transferase-mediated 
dUTP (2′-deoxyuridine 5′-triphosphate) nick-end labeling (TUNEL) assay, we determined that 
NAE18:2 reduces the number of apoptotic RGC layer neurons in response to glutamate and 
conclude that NAE18:2 is a neuroprotective compound with potential for treating glaucomatous 
retinopathy.
Keywords: neuroprotection, glutamate, calcium signaling, immunocytochemistry, eye, vision, 
glaucoma.
The most widespread form of glaucoma, primary open-angle glaucoma, is characterized 
by increased intraocular pressure (IOP), optic disc cupping, retinal ganglion cell (RGC) 
death and visual loss.1 Glaucoma is often preceded by elevated IOP followed by optic 
nerve damage, glial activation, oxidative stress, and excitotoxicity.2–6 Several studies 
have revealed that glutamate-induced RGC excitotoxicity occurs in animal models.5,7–11 
As a result, RGC neuroprotection against excitotoxicity and other pathophysiological 
processes in glaucoma is considered a viable therapeutic strategy for glaucoma.12,13 
Inhibition of NMDA (N-methyl-D-aspartate) receptors with the selective antago-
nists MK-801 or memantine can reduce excitotoxic RGC death in animal models of 
glaucoma.5,8,10,11,14 Previous work from our laboratory reveals that RGCs in postnatal 
mouse retinal explant cultures are susceptible to excitotoxicity.15
N-acylethanolamides (NAEs) are lipid-signaling molecules involved in numer-
ous physiological functions in mammals, including cytoprotection. Some NAEs, and 
their precursors, are produced in rat brain in response to excitotoxicity, ischemia, and 
stroke,16–21 suggesting their possible role in cytoprotection.
Unlike the well characterized endocannabinoid NAE 20:4, the molecular target 
of some NAE species, such as palmitoylethanolamine (NAE 16:0) and NAE 18:2, is 
not known. Strong evidence for noncannabinoid NAE-mediated cytoprotection comes Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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from multiple studies. For example, NAE 16:0 protects the 
hippocampal cell line, HT22, from oxidative stress, and it 
activates the neuroprotective Akt and ERK1/2 pathways.22 
NAE16:0 administration prior to or after middle cerebral 
artery occlusion in rats leads to significant reduction in 
stroke severity.23
Many different NAEs are produced in the retina.24 In 
addition, receptors for NAEs and enzymes involved in 
NAE metabolism are expressed in the retina, suggesting 
that NAEs may provide protection of retinal neurons in 
diseases of the eye.25–30 For example, activation of cannabi-
noid receptor type 1 (CB1) with a synthetic CB1 receptor 
agonist protects retina neurons from excitotoxicity and 
oxidative stress.31
Here, we report that the naturally occurring NAE 18:2 
protects neurons in the RGC layer against glutamate exci-
totoxicity in organotypic retina cultures. We determined 
that NAE 18:2 reduced the number of apoptotic RGC layer 
neurons in response to glutamate by TUNEL (terminal deoxy-
nucleotidyl transferase-mediated dUTP [2′-deoxyuridine 
5′-triphosphate] nick-end labeling) histochemistry, indicat-
ing that NAE 18:2 may be a neuroprotective compound 
with potential for treating acute and chronic RGC damage 
as seen in retinal ischemia and glaucomatous retinopathy, 
respectively.
Materials and methods
Animals and tissue culture
All animal procedures were conducted in accordance with 
National Institutes of Health (NIH) and institutional regula-
tions on Care and Use of Laboratory Animals. Whole retinas 
were isolated from C57BL/6 mice and maintained as orga-
notypic cultures as described elsewhere.15 In brief, C57BL/6 
mice (P10–P14) were euthanized by overexposure to CO2 
and decapitated. Freshly enucleated eyes were rinsed in cold 
Hank’s Balanced Salt Solution (HBSS) (HyClone Inc, Logan, 
UT) under sterile conditions. The retinas were removed 
from the eyes, and incisions were introduced in the shape 
of a Maltese cross to flatten the retina tissue. Retinas were 
placed onto poly-D-lysine/laminin-coated glass coverslips 
(BD Bioscience, Bedford, MA) with the ganglion cell layer 
facing the coverslip. The retina was permitted to attach to 
the coverslip for 30 minutes at room temperature in 20 µL 
of culture medium (Neurobasal-A Medium, Gibco, Carlsbad, 
CA with 2% DHS [donor horse sera], B27 supplement, and 
penicillin-streptomycin-fungizone). Retinas were incubated 
at 37°C with 5% CO2 for 7 days in vitro, and culture media 
was replaced every other day.
experimental groups
Retinas from C57Bl/6 mice were treated with NAE 18:2 
(or ethanol vehicle) over a range of physiologically relevant 
concentrations (20–120 µM) for 6 hours prior to addition 
of and during exposure to 100 µM glutamate for 24 hours 
(30 hour NAE 18:2 exposure total). The 6-hour NAE 18:2 
pretreatment was selected because previous studies with other 
NAEs indicate that a 6-hour pretreatment protects a neuronal 
cell line against oxidative stress.22 Additionally, retinas 
received NAE 18:2 treatment (or ethanol vehicle) 24 hours 
prior to addition of and during exposure to a 24-hour gluta-
mate treatment or at the same time as glutamate treatment for 
24 hours (co-treatment paradigm; 48-hour NAE 18:2 exposure 
total) in order to determine a therapeutic window.
Cell viability measurements
Identification of neurons in the RGC layer in explants was 
determined using cell specific immunohistochemistry, and 
loss of neurons in the RGC layer was assessed using the 
TUNEL assay as described elsewhere.15,32 Retinas attached to 
coverslips were fixed in 4% paraformaldehyde and subjected 
to the TUNEL assay to detect apoptotic cells as described 
elsewhere.15 Coverslips were mounted onto microscope slides 
using Prolong Gold antifade mounting medium containing 
DAPI (4′,6-diamidino-2-phenylindole) (Molecular Probes, 
Eugene, OR) to visualize nuclei. Fluorescent and differential 
interference contrast (DIC) images were acquired with an epi-
fluorescence microscope (Olympus IX70, Japan) using digital 
microphotography (Hamamatsu, Japan), and analysis of images 
was conducted using SimplePCI (Compix Inc, Image Systems, 
Sewickley, PA). Images from four 8000 µM2 regions from each 
condition were used for analysis. Background fluorescence of 
vehicle control images was subtracted from micrographs to 
better visualize TUNEL fluorescence. TUNEL-positive RGCs 
were manually counted in each micrograph, and data were 
graphed with standard errors in Microsoft Excel. Statistical 
analysis between treatment groups was determined using a 
one-way analysis of variance (GraphPad Prism 5.01).
Results
evaluation of glutamate and nAe 18:2 
on the viability of rgC layer neurons 
in retinal explant cultures
To determine whether NAE 18:2 alone had an effect on the 
viability of neurons in the RGC layer, retina explants were 
treated with NAE 18:2 (or ethanol vehicle) for 24 hours 
followed by TUNEL assay to detect apoptosis (Figure 1). Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Exposure of explants to NAE 18:2 did not result in apoptotic 
retinal cells compared with the vehicle control (Figure 1). To 
verify glutamate sensitivity of RGC layer neurons, explants 
were exposed to glutamate (100 µM) for 24 hours. Glutamate 
exposure led to significant RGC apoptosis as determined by 
the TUNEL assay (Figure 1).
nAe 18:2 protects rgC layer neurons 
against glutamate-induced excitotoxicity
Retinas were treated 6 hours prior to glutamate insult with 
20–120 µM NAE 18:2 (along with vehicle) to determine 
whether physiological concentrations affect neuronal viability. 
Previous studies with a structurally similar NAE reveal that 
a 6-hour preincubation is neuroprotective, thus providing a 
rationale for a 6-hour NAE 18:2 preincubation.22 Preincubation 
with NAE 18:2, at 6 hours prior to glutamate exposure resulted 
in a dose-dependent decrease in the number of TUNEL-labeled 
(apoptotic) RGCs (Figure 2). Retinas exposed to NAE 18:2 
at concentrations above 40 µM exhibit dramatically reduced 
TUNEL labeling of neurons in the RGC layer (Figure 2). An 
NAE 18:2 concentration of 40 µM approximates a high physi-
ological concentration, thus avoiding the need for potentially 
toxic supra-physiological exposures. These results suggest that 
6-hour NAE 18:2 pretreatment dose-dependently increases 
neuronal viability after 100 µM glutamate-mediated induction 
of apoptosis of neurons in the RGC layer.
nAe 18:2 preincubation is critical 
for its neuroprotective effect
To further determine the requirement for NAE 18:2 
  preincubation in RGC layer neuroprotection, retina explants 
were pretreated with 40 µM NAE 18:2 at 24 hours prior to and 
subsequently during glutamate exposure (24-hour pretreat-
ment) or administered at the same time as glutamate treatment 
(no preincubation). Retina explants pretreated with NAE 18:2 
for 24 hours prior to glutamate insult exhibited significantly 
reduced RGC apoptosis, whereas retinas co-treated with NAE 
18:2 and glutamate exhibited no protection of neurons in the 
RGC layer against glutamate-induced apoptosis (Figure 3). 
There was, however, a trend toward a reduction in neuronal 
apoptotis when retinas were co-treated with 80 µM NAE 
18:2 and glutamate (Figure 3B).
Discussion
Here, we show that NAE 18:2 protects RGC layer neurons 
from glutamate-induced apoptosis in retinal explant cultures. 
We determined that NAE 18:2 treatment must precede gluta-
mate exposure to elicit its neuroprotective effect. The highly 
significant, dose-dependent reduction of glutamate-induced 
death of RGC layer neurons by treatment with NAE 18:2 
reveals a neuroprotective function for NAEs that do not bind 
to cannabinoid receptors. These results provide a rationale 
for the use of NAEs as potential therapeutic compounds in 
acute and chronic neurodegenerative diseases of the retina. 
Whether or not excitotoxic RGC death occurs in glaucoma 
has been controversial.33,34 Here, we observed RGC layer 
neuron death at glutamate concentrations consistent with 
activation of ionotropic glutamate receptors and not delayed 
oxidative glutamate toxicity due to glutathione depletion.
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Figure  1  neurons  in  the  rgC  layer  are  sensitive  to  glutamate  excitotoxicity. 
A) exposure of retinas to 40 µM nAe 18:2 or ethanol vehicle does not affect 
viability of neurons in the rgC layer. glutamate (100 µM) exposure, however, 
causes  apoptotic  cell  death  in  the  rgC  layer  of  retina  explants  (red  arrows). 
B) Quantitative summary data revealing the lack of toxicity of nAe 18:2 or its 
vehicle as well as the degree of cell death in the rgC layer measured as the number 
of TUNEL-positive cells in retinas exposed to glutamate. RGCs were identified by 
Thy 1.2 and neurofilament-68 kDa immunoreactivity and location.15,32 
Notes: scale bar: 50 µM. *denotes P , 0.05, as determined with a one-way analysis 
of variance test.
Abbreviations: DiC, differential interference contrast; nAe, N-acylethanolamide; 
rgC, retinal ganglion cell; TUneL, terminal deoxynucleotidyl transferase-mediated 
dUTP (2′-deoxyuridine 5′-triphosphate) nick-end labeling – green fluorescence.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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NAEs, as well as the receptors and enzymes involved in 
NAE function, are present in the retina.24–30 Human eye samples 
from patients with diabetic retinopathy and age-related macular 
degeneration exhibit elevated levels of NAEs, suggesting that 
they may be involved in an   endogenous   protective response 
to eye injury.35 Interestingly, high IOP-induced ischemia in 
rats results in reduced anandamide (NAE 20:4) levels due 
to elevated fatty acid amide hydrolase (FAAH) expression 
subsequently contributing to RGC loss.36 This suggests that 
endocannabinoid NAEs are neuroprotective in the ischemic 
retina. This is further evidenced by improved RGC viability 
in the ischemic retina following pharmacological inhibition 
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Figure 2 nAe 18:2 protects rgC layer neurons from glutamate excitotoxicity. 
A) exposure of retinas to 100 µM glutamate resulted in a dramatic increase in 
rgC layer neuron death (red arrows). Preincubation of retinas with nAe 18:2 for 
6 hours prior to glutamate exposure resulted in a dose-dependent decrease in 
the number apoptotic, TUneL-positive rgC layer neurons, with high physiological 
concentrations reducing the number of apoptotic neurons. RGCs were identified 
by Thy 1.2 immunoreactivity and location.15,32 B) Quantitative summary data for 
the nAe 18:2-mediated neuroprotection from glutamate toxicity as measured by 
TUneL histochemistry. 
Notes: *denotes P , 0.05, as determined by a one-way analysis of variance test. 
scale bar: 50 µM.
Abbreviations: DiC, differential interference contrast; nAe, N-acylethanolamide; 
rgC, retinal ganglion cell; TUneL, terminal deoxynucleotidyl transferase-mediated 
dUTP (2′-deoxyuridine 5′-triphosphate) nick-end labeling – green fluorescence.
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Figure  3  nAe  18:2  preincubation  is  required  for  protection  of  rgC  layer 
neurons against glutamate excitotoxicity. nAe 18:2 preincubation is critical for its 
neuroprotective effect. A) retina explants were either pretreated for 24 hours 
(On) with 40 µM nAe 18:2 prior to and during glutamate exposure or at the 
onset of glutamate exposure (no pretreatment). All glutamate exposures were for 
24 hours, and nAe 18:2 was present during the glutamate exposure period. note 
the lack of protection without pretreatment (red arrows). B) Quantitative summary 
data revealing the requirement for nAe 18:2 protection of rgC layer neurons 
against glutamate. 
Notes: *denotes P , 0.05, as determined by a one-way analysis of variance test. 
scale bar: 50 µM.
Abbreviations: DiC, differential interference contrast; nAe, N-acylethanolamide; 
On,  overnight;  rgC,  retinal  ganglion  cell;  TUneL,  terminal  deoxynucleotidyl 
transferase-mediated dUTP (2′-deoxyuridine 5′-triphosphate) nick-end labeling – 
green fluorescence.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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of FAAH.36 Altogether, data presented here and from others 
provide evidence for a neuroprotective role for NAEs against 
diseases of the retina such as glaucoma.
The neuroprotective mechanism of action of NAE 18:2 
is not clear at this time. Others have proposed that NAE 18:2 
is a vanilloid receptor 1 (VR1) agonist or that it reduces the 
degradation of the endocannabinoid NAE, NAE 20:4, by 
FAAH.37,38 NAE 20:4 neuroprotection is mediated primarily 
through activation of CB1 and subsequent downregulation 
of cyclic adenosine monophosphate (cAMP) production 
and protein kinase A (PKA) activation.39,40 In addition, CB1 
activation can inhibit voltage gated calcium channels, activate 
inward rectifying potassium channels, and activate various 
protein kinases.41–45 Most NAEs, including NAE 16:0 and 
NAE 18:2, do not activate cannabinoid receptors.46 Activation 
of VR1 leads to apoptosis in a variety of cell culture model 
systems, thus making VR1 activation an unlikely target for 
NAE 18:2 protective effects.47,48
We previously determined that, in the HT-22 neuronal cell 
line, NAE16:0 is neuroprotective against oxidative stress by a 
mechanism independent of cannabinoid receptor involvement 
and correlating with Akt and ERK1/2 activation.22 Furthermore, 
NAE 16:0 administration reduces infarct volume and improves 
behavioral deficits independent of CB1 or VR1 in a rat model 
of ischemic stroke.23 CB1 is expressed in vascular smooth 
muscles of cerebral arteries.49 Peripheral CB1 activation by 
systemic administration of NAE 20:4 dilates cerebral   arteries.50 
  Neuroprotection afforded by NAE 16:0 against ischemic 
stroke is not blocked by inhibitors of CB1 or VR1, suggesting 
that the protection is not due to cerebral vasodilation.23 The 
retina explant model used in the present study excludes any 
vasodilatative or hemodynamic mechanism of action for the 
neuroprotective effect of NAE 18:2 in the retina. The mecha-
nism of action for NAE 18:2 neuroprotection is likely a direct 
effect on RGCs similar to that previously observed with other 
noncannabinoid NAEs in a neuronal cell line model.22
Altogether, the data presented here and from previous 
studies indicate that neuroprotection by some NAEs is inde-
pendent of cannabinoid receptor activation and is mediated 
by an unknown mechanism. The diversity of NAEs and their 
potential functional targets may provide a variety of new 
therapeutic targets for the treatment of neurodegenerative 
diseases, including glaucomatous retinopathy.
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